Neuroprotective effects of dexmedetomidine against glutamate agonist-induced neuronal cell death are related to increased astrocyte brain-derived neurotrophic factor expression

Anesthesiology

Volumn 118, Issue 5, 2013, Pages 1123-1132

  Degos, Vincent ^a,b,c,d   Le Charpentier, Tifenn ^a,b,c,d   Chhor, Vibol ^a,b,c   Brissaud, Olivier ^a,b,c   Lebon, Sophie ^a,b,c   Schwendimann, Leslie ^a,b,c   Bednareck, Nathalie ^a,b,c,d   Passemard, Sandrine ^a,b,c,e   Mantz, Jean ^a,b,c,d   Gressens, Pierre ^a,b,c,d,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PremUP   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR 4; BRAIN DERIVED NEUROTROPHIC FACTOR 5; DEXMEDETOMIDINE; IBOTENIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN CORTEX LESION; BRAIN INJURY; DRUG EFFECT; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ASTROCYTES; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL DEATH; CELLS, CULTURED; DEXMEDETOMIDINE; EXCITATORY AMINO ACID AGONISTS; FEMALE; GENE EXPRESSION; HYPNOTICS AND SEDATIVES; IBOTENIC ACID; MALE; MAP KINASE SIGNALING SYSTEM; MICE; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; RNA; TRANSCRIPTION, GENETIC;

EID: 84877578542     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e318286cf36     Document Type: Article

References (42)

1. Johnston MV, Nakajima W, Hagberg H: Mechanisms of hypoxic neurodegeneration in the developing brain. Neuroscientist 2002; 8:212-20
2. Luján R, Shigemoto R, López-Bendito G: Glutamate and GABA receptor signalling in the developing brain. Neuroscience 2005; 130:567-80
3. Jevtovic-Todorovic V, Hartman RE, Izumi Y, Benshoff ND, Dikranian K, Zorumski CF, Olney JW, Wozniak DF: Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci 2003; 23:876-82
4. Mellon RD, Simone AF, Rappaport BA: Use of anesthetic agents in neonates and young children. Anesth Analg 2007; 104:509-20
5. Lu LX, Yon JH, Carter LB, Jevtovic-Todorovic V: General anesthesia activates BDNF-dependent neuroapoptosis in the developing rat brain. Apoptosis 2006; 11:1603-15
6. Degos V, Loron G, Mantz J, Gressens P: Neuroprotective strategies for the neonatal brain. Anesth Analg 2008; 106:1670-80
7. Ramsay MA, Luterman DL: Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology 2004; 101:787-90
8. Walker SM, Howard RF, Keay KA, Fitzgerald M: Developmental age influences the effect of epidural dexmedetomidine on inflammatory hyperalgesia in rat pups. Anesthesiology 2005; 102:1226-34
9. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, Maze M: Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 2004; 502:87-97
10. Laudenbach V, Mantz J, Lagercrantz H, Desmonts JM, Evrard P, Gressens P: Effects of alpha(2)-adrenoceptor agonists on perinatal excitotoxic brain injury: Comparison of clonidine and dexmedetomidine. Anesthesiology 2002; 96:134-41
11. Paris A, Mantz J, Tonner PH, Hein L, Brede M, Gressens P: The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg 2006; 102:456-61
12. Dahmani S, Rouelle D, Gressens P, Mantz J: Effects of dexmedetomidine on hippocampal focal adhesion kinase tyrosine phosphorylation in physiologic and ischemic conditions. Anesthesiology 2005; 103:969-77
13. Rajakumaraswamy N, Ma D, Hossain M, Sanders RD, Franks NP, Maze M: Neuroprotective interaction produced by xenon and dexmedetomidine on in vitro and in vivo neuronal injury models. Neurosci Lett 2006; 409:128-33
14. Juric DM, Loncar D, Carman-Krzan M: Noradrenergic stimulation of BDNF synthesis in astrocytes: Mediation via alpha1-and beta1/beta2-adrenergic receptors. Neurochem Int 2008; 52:297-306
15. Dommergues MA, Patkai J, Renauld JC, Evrard P, Gressens P: Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium. Ann Neurol 2000; 47:54-63
16. Sokoloff G, Blumberg MS, Boline EA, Johnson ED, Streeper NM: Thermoregulatory behavior in infant Norway rats (Rattus norvegicus) and Syrian golden hamsters (Mesocricetus auratus): Arousal, orientation, and locomotion. J Comp Psychol 2002; 116:228-39
17. Bollen B, Bouslama M, Matrot B, Rotrou Y, Vardon G, Lofaso F, Van den Bergh O, D'Hooge R, Gallego J: Cold stimulates the behavioral response to hypoxia in newborn mice. Am J Physiol Regul Integr Comp Physiol 2009; 296:R1503-11
18. Fontaine RH, Cases O, Lelièvre V, Mesplès B, Renauld JC, Loron G, Degos V, Dournaud P, Baud O, Gressens P: IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis. Cell Death Differ 2008; 15:1542-52
19. Bekker A, Sturaitis MK: Dexmedetomidine for neurological surgery. Neurosurgery 2005; 57(1 Suppl):1-10; discussion 1-10
20. Zhang Y, Kimelberg HK: Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia. Curr Neuropharmacol 2005; 3:317-23
21. Talke P, Bickler PE: Effects of dexmedetomidine on hypoxiaevoked glutamate release and glutamate receptor activity in hippocampal slices. Anesthesiology 1996; 85:551-7
22. Guo S, Lo EH: Dysfunctional cell-cell signaling in the neurovascular unit as a paradigm for central nervous system disease. Stroke 2009; 40(3 Suppl):S4-7
23. Degos V, Favrais G, Kaindl AM, Peineau S, Guerrot AM, Verney C, Gressens P: Inflammation processes in perinatal brain damage. J Neural Transm 2010; 117:1009-17
24. Trendelenburg G, Dirnagl U: Neuroprotective role of astrocytes in cerebral ischemia: Focus on ischemic preconditioning. Glia 2005; 50:307-20
25. Engelhard K, Werner C, Kaspar S, Möllenberg O, Blobner M, Bachl M, Kochs E: Effect of the alpha2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats. Anesthesiology 2002; 96:450-7
26. Hertz L, Lovatt D, Goldman SA, Nedergaard M: Adrenoceptors in brain: Cellular gene expression and effects on astrocytic metabolism and [Ca(2+)]i. Neurochem Int 2010; 57:411-20
27. Rex CS, Lin CY, Kramár EA, Chen LY, Gall CM, Lynch G: Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus. J Neurosci 2007; 27:3017-29
28. Kolarow R, Brigadski T, Lessmann V: Postsynaptic secretion of BDNF and NT-3 from hippocampal neurons depends on calcium calmodulin kinase II signaling and proceeds via delayed fusion pore opening. J Neurosci 2007; 27:10350-64
29. Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, Hempstead BL, Lu B: Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 2005; 8:1069-77
30. Yang J, Siao CJ, Nagappan G, Marinic T, Jing D, McGrath K, Chen ZY, Mark W, Tessarollo L, Lee FS, Lu B, Hempstead BL: Neuronal release of proBDNF. Nat Neurosci 2009; 12:113-5
31. Reyland ME, Barzen KA, Anderson SM, Quissell DO, Matassa AA: Activation of PKC is sufficient to induce an apoptotic program in salivary gland acinar cells. Cell Death Differ 2000; 7:1200-9
32. Dahmani S, Paris A, Jannier V, Hein L, Rouelle D, Scholz J, Gressens P, Mantz J: Dexmedetomidine increases hippocampal phosphorylated extracellular signal-regulated protein kinase 1 and 2 content by an alpha 2-adrenoceptor- independent mechanism: Evidence for the involvement of imidazoline I1 receptors. Anesthesiology 2008; 108:457-66
33. Dahmani S, Rouelle D, Gressens P, Mantz J: Characterization of the postconditioning effect of dexmedetomidine in mouse organotypic hippocampal slice cultures exposed to oxygen and glucose deprivation. Anesthesiology 2010; 112:373-83
34. Venn RM, Karol MD, Grounds RM: Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret. Br J Anaesth 2002; 88:669-75
35. Hansen TM, Moss AJ, Brindle NP: Vascular endothelial growth factor and angiopoietins in neurovascular regeneration and protection following stroke. Curr Neurovasc Res 2008; 5:236-45
36. Li B, Du T, Li H, Gu L, Zhang H, Huang J, Hertz L, Peng L: Signalling pathways for transactivation by dexmedetomidine of epidermal growth factor receptors in astrocytes and its paracrine effect on neurons. Br J Pharmacol 2008; 154:191-203
37. Madara JC, Levine ES: Presynaptic and postsynaptic NMDA receptors mediate distinct effects of brain-derived neurotrophic factor on synaptic transmission. J Neurophysiol 2008; 100:3175-84
38. Aarts MM, Tymianski M: Molecular mechanisms underlying specificity of excitotoxic signaling in neurons. Curr Mol Med 2004; 4:137-47
39. Lipton SA: Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci 2007; 8:803-8
40. Lipton SA, Rosenberg PA: Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330:613-22
41. David KK, Andrabi SA, Dawson TM, Dawson VL: Parthanatos, a messenger of death. Front Biosci 2009; 14:1116-28
42. Andrabi SA, Kang HC, Haince JF, Lee YI, Zhang J, Chi Z, West AB, Koehler RC, Poirier GG, Dawson TM, Dawson VL: Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nat Med 2011; 17:692-9